Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children

• Status: Not yet recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tongji Hospital
• Treatments: Esketamine; Propofol; Remifentanil

Criteria

Inclusion Criteria:

• Age 0-17;

• ASA Class I-II;

• Sign the informed consent form.

Exclusion Criteria:

• Patients with high risk of stomach satiety and reflux aspiration;

• Patients allergic to the study drug;

• Obesity or severe malnutrition;

• Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;

• Hypertension without treatment;

• Abnormal liver and kidney function (index ≥ 2 times the upper limit of normal reference range);

• Other congenital diseases or acute and chronic diseases that affect the observation of curative effect;

• Participate in other clinical studies within 4 weeks.